Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)

Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Thursday. $99.25 million flowed into the stock on the tick-up and $264.36 million flowed out of the stock on the tick-down, for a money net flow of $165.11 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 4th highest net out-flow for the day. Johnson & Johnson traded up $0.81 for the day and closed at $138.10

Several research firms have issued reports on JNJ. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective for the company in a research report on Wednesday, November 28th. Morgan Stanley cut their price objective on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 2nd. Barclays reiterated an “equal weight” rating and issued a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Wells Fargo & Co reiterated an “outperform” rating and issued a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $142.81.

The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. The firm has a market cap of $371.42 billion, a price-to-earnings ratio of 16.88, a price-to-earnings-growth ratio of 2.12 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.02. The company had revenue of $20.39 billion for the quarter, compared to analyst estimates of $20.27 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. Johnson & Johnson’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.74 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 8.57 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th were issued a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend was Monday, February 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 44.01%.

Johnson & Johnson announced that its board has authorized a stock buyback plan on Monday, December 17th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 1.5% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.

A number of institutional investors have recently bought and sold shares of the business. Warren Averett Asset Management LLC boosted its stake in Johnson & Johnson by 3.4% in the 2nd quarter. Warren Averett Asset Management LLC now owns 15,052 shares of the company’s stock worth $1,826,000 after buying an additional 488 shares during the last quarter. West Branch Capital LLC boosted its stake in Johnson & Johnson by 109.0% in the 2nd quarter. West Branch Capital LLC now owns 17,920 shares of the company’s stock worth $2,174,000 after buying an additional 9,345 shares during the last quarter. Windsor Capital Management LLC boosted its stake in Johnson & Johnson by 6.0% in the 2nd quarter. Windsor Capital Management LLC now owns 9,291 shares of the company’s stock worth $1,128,000 after buying an additional 523 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its stake in Johnson & Johnson by 212.7% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 1,498,023 shares of the company’s stock worth $181,770,000 after buying an additional 1,019,002 shares during the last quarter. Finally, Isthmus Partners LLC boosted its stake in Johnson & Johnson by 0.8% in the 2nd quarter. Isthmus Partners LLC now owns 58,283 shares of the company’s stock worth $7,072,000 after buying an additional 459 shares during the last quarter. 66.43% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://sportsperspectives.com/2019/03/21/traders-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: How is net asset value different from market price?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.